NGL Fine-Chem Limited reported a strong financial performance for Q4 and FY26, driven by higher volumes and improved capacity utilization. Revenue from operations for Q4 FY26 stood at ₹149.23 crores, a 57% increase from ₹94.97 crores in Q4 FY25. Profit after tax for the quarter rose to ₹13.49 crores, compared to ₹0.54 crores in the corresponding period of the previous year. For the full fiscal year FY26, the company achieved a revenue of ₹500.95 crores, reflecting a 36% growth over FY25, while profit after tax grew by 128% to ₹48.13 crores.

The disclosure was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The earnings conference call was held on May 25, 2026, to discuss the operational and financial performance.

Financial Performance

The company reported significant margin expansion during the quarter. EBITDA for Q4 FY26 came in at ₹21.41 crores, compared to ₹6.32 crores in Q4 FY25, with an EBITDA margin of 14.35%. This represents an expansion of 769 basis points year-on-year. For the full year FY26, EBITDA stood at ₹72.69 crores, more than doubling from ₹33.87 crores in FY25, with a margin of 14.51%.

Operational Highlights

Management attributed the growth to higher volumes across the product portfolio and geographies. Animal API contributed 95% of the revenues during the quarter. The company noted that geopolitical developments led to increased freight costs and raw material prices, impacting margins sequentially. However, partial price pass-through was secured in the first quarter of the current financial year.

Capacity Expansion

Phase I of the expansion programme is operational and contributing to volumes. Phase II of the Greenfield expansion at Tarapur faced delays due to gas and labour shortages, with commissioning now scheduled for early Q2 FY27. Commercial production from Phase II is expected to commence in H2 FY27. The total planned capex for the expansion is ₹210 crores, of which ₹182.75 crores has been invested up to Q4 FY26.

NGL Fine-Chem Limited has reported its audited financial results for the quarter and year ended March 31, 2026. The company's consolidated net profit for the year surged to ₹4,812.67 lakh, a significant increase of 128% from ₹2,112.43 lakh in the previous year. Revenue from operations for the year stood at ₹51,568.29 lakh compared to ₹37,688.70 lakh in FY25. The board has recommended a final dividend of ₹1.75 per share.

Financial Performance

For the quarter ended March 31, 2026, NGL Fine-Chem delivered a strong operational performance, with Q4 revenue rising 61.4% year-on-year to ₹15,169.20 lakh. This growth was driven entirely by volume expansion, marking the third consecutive quarter of robust volume growth. Q4 EBITDA increased to ₹214.10 lakh from ₹63.20 lakh in the same period last year. The EBITDA margin expanded to 14.1% from 6.7% year-on-year. Consolidated net profit for the quarter came in at ₹1,348.56 lakh, compared to ₹54.36 lakh in the corresponding quarter of the previous year.

The following table summarises the key consolidated financial metrics for the full year and the quarter:

Operational Highlights

The company reported that Animal API segment revenue constituted 95% of the total mix in Q4FY26. Geographically, Asia accounted for 43% of the revenue, followed by India at 23% and Rest of the World at 26%. Management noted that while geopolitical volatility increased freight and raw material costs, partial price pass-through was achieved in the first quarter. Phase I of the capex programme is contributing to operations, while Phase II commissioning is now scheduled for early Q2FY27.

Key Meeting Decisions

The board has scheduled the 45th Annual General Meeting (AGM) for Tuesday, August 25, 2026, via Video Conferencing. The record date for determining eligibility for the AGM and dividend payment is Tuesday, August 18, 2026. The register of members and share transfer books will remain closed from Wednesday, August 19, 2026, to Tuesday, August 25, 2026. Additionally, the board approved the reappointment of Mr. Rajesh Lawande as Whole-Time Director and Mrs. Sarala Menon as Independent Director, subject to shareholder approval.